China (Mainland)
Diamondsupplier 
factory supply GMP,DMF Emtritabine CAS NO.143491-57-0
- Min.Order: 1 Kilogram
- Payment Terms: L/C,T/T,Other
- Product Details
Keywords
- Emtritabine
- hydrocortisone acetate
- 143491-57-0
Quick Details
- ProName: factory supply GMP,DMF Emtritabine
- CasNo: 143491-57-0
- Molecular Formula: C8H10FN3O3S
- Appearance: White crystallization
- Application: anti-HIV drugs
- DeliveryTime: in two weeks
- PackAge: 1kg/tin
- Port: SHANGHAI BEIJING
- ProductionCapacity: 1 Metric Ton/Day
- Purity: USP/EP/BP
- Transportation: AIR SEA TRAIN
- LimitNum: 1 Kilogram
Superiority
We are very compeitive on Emtritabine.Our mfr is GMP certified for this item with DMF document.
| Product Name: | Emtricitabine |
| CAS: | 143491-57-0 |
| MF: | C8H10FN3O3S |
| MW: | 247.25 |
| EINECS: | 604-363-1 |
| Product Categories: | Inhibitors;Carbohydrates & Derivatives;Intermediates & Fine Chemicals;Chiral Reagents;Heterocycles;Sulfur & Selenium Compounds;Pharmaceuticals |
| Mol File: | 143491-57-0.mol |
Details
| Description | Emtricitabine is a nucleoside reverse transcriptaseinhibitor (NRTI) which has been marketed for the prevention and treatment of HIV infection. It also exhibits clinical activity against the hepatitis B virus (HBV) (not yet approved by FDA).Emtricitabine is a synthetic nucleoside analogue of cytidine. It can be phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate, which competes with the natural substrate deoxycytidine 5'-triphosphate and incorporates into nascent viral DNA, causing early chain termination. Through doing this, it not only lowers the amount of HIV, but also indirectly increases the number of immune system cells (called T cells or CD4+ T-cells). |
| New anti-HIV drugs | Emtricitabine was a novel nucleoside reverse transcriptase inhibitor successfully developed by Gilead Sciences, Inc., belonging to an anti-viral drugs and exhibits antiviral activity on HIV-1, HIV-2 and HBV. Its antiviral activity exhibits that it can specifically anti-HIV-1, HIV-2 and HBV while even with its drug concentration being raised to 100 mmol/L, it still exhibit no activity against HSV-1, HSV-2, HCMV, VZV, corona, yellow fever virus, respiratory syncytial virus, Rota, and influenza virus or rhinovirus. Even at a concentration lower than micromolar, the drug still exhibits potent inhibitor effect against the LAV strain and IIIB 1 of HIV virus and the ROD2 strain and ZY virus strain of HIV-2 with an IC50 value lower being 95 times lower than that of AZT (zidovudine). It has been increasingly become the focus of the assessment of new drugs that whether new anti-HIV drug will produce cross-resistance to other kinds of antiviral resistant strains such as AZT, etc. The cross-resistance test of emtricitabine against AZT-resistant strains has demonstrated that although IC50 values for these resistant strains have been increased slightly, all kinds of virus strains are still relatively sensitive to emtricitabine. Instead, emtricitabine-resistant viral strains will exhibit significant cross-resistance to antiviral 3TC (lamivudine), but are still sensitive to AZT. Studies have shown that the drug can be used together with AZT with synergistic effect. Emtricitabine exhibited strong antiviral activity in HBV generating cell lines HepG22.2.15 (PSA subspecies). It can dose-dependently reduce the number of extracellular and intracellular HBVDNA with the IC50 value being 10nmol/L; this value was comparable to another kind of HBV replication inhibitor 3TC. Interferon α nl (Wellferon), α 2a (Ro feron), α 2b (Intron A) can all the production of inhibit HBV viral particles and the accumulation of the intracellular replication virus in the chronic producing cells intracellular production. Combination of them associated with emtricitabine can produce a synergistic effect. The in vivo anti-hepatitis activity of emtricitabine is investigated through the anti-HBV action in a kind of chimeric mouse model as well as the action of anti-woodchuck hepatitis virus (WHV) function in natural infected prairie dogs. In the mouse model, use different doses for oral administration of this drug to mouse of immune deficiency and carrying human tumors as well as producing human HBV, with the antibody capture/PcR experiment, it was found that the blood HBVDNA (Dane particle) was reduced in a dose-dependent manner with even a low dose of 3.5 mg/(kg • d) also being able to produce significant inhibition while the level of intracellular replicated HBVDNA also exhibited a dose-dependent decrease; however, even at the highest dose (89 mg/(kg • d )), the tumor size remained unchanged, suggesting that the drug has selective anti-HBV activity. |
